(A) Oncomine microarray TGFBR3 expression analysis in human benign nevi and primary melanoma tissues. See Supplemental Table 2. (B) DNA hybridization blot analysis of TGFBR3 mRNA levels in normal human skin (N) and melanoma tumor tissues (T). (C) TGFBR3 IHC of human benign nevi, primary melanoma, and metastatic melanoma tumor tissues. 100 core tissues were evaluated. Representative ×20 fields are also shown. (D) B16-mOVA-TGFBR3 tumor growth relative to B16-mOVA control (ctrl) and B16/F10 (B16) tumors in syngeneic hosts. 5–6 tumors/condition. Representative of 3 independent experiments. (E) qRT-PCR of Cd8 and Foxp3 in B16-mOVA-TGFBR3 versus B16-mOVA tumors. 3 tumors/condition. Representative of 2 independent experiments. (F) CD8 and FOXP3 IHC of B16-mOVA-TGFBR3, B16-mOVA, and B16/F10 tumors. 10 fields/tumor, 3 tumors/condition. (G) Kb-OVA257–264–specific CD8+ T cell tetramer analysis of resected splenic and TDLN tissues from B16-mOVA-TGFBR3, B16-mOVA, and B16/F10 tumor-bearing mice. 3–6 mice/group. Representative of 2 independent experiments. Data are mean ± SEM. *P < 0.05, 2-tailed Student’s t test (A, E, and F), 1-way ANOVA (C, D, and G).